Equities Analysts Issue Forecasts for Nuwellis Q1 Earnings

Nuwellis, Inc. (NASDAQ:NUWE) – Equities research analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for Nuwellis in a research note issued to investors on Monday, January 13th. Roth Capital analyst J. Aschoff anticipates that the company will earn ($0.30) per share for the quarter. The consensus estimate for Nuwellis’ current full-year earnings is ($9.91) per share. Roth Capital also issued estimates for Nuwellis’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.18) EPS, FY2027 earnings at $0.41 EPS and FY2029 earnings at $1.78 EPS.

Nuwellis (NASDAQ:NUWE) last released its quarterly earnings data on Monday, November 11th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $2.62. Nuwellis had a negative return on equity of 28,159.25% and a negative net margin of 169.54%. The company had revenue of $2.37 million during the quarter, compared to the consensus estimate of $2.40 million. During the same quarter in the prior year, the firm posted ($63.29) earnings per share.

Nuwellis Price Performance

Nuwellis stock opened at $1.07 on Wednesday. The business has a 50 day moving average of $1.29 and a 200-day moving average of $1.87. Nuwellis has a 1 year low of $0.92 and a 1 year high of $27.61. The company has a market capitalization of $4.68 million, a P/E ratio of -0.01 and a beta of 0.32.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.